Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Postpartum hemorrhage increases 28% between 1995 and 2004

A new study of U.S. maternal outcomes after vaginal and cesarean deliveries published in the May 2010 issue of Anesthesia & Analgesia, a peer-reviewed academic journal, shows that between 1995 and 2004, postpartum hemorrhage (excessive blood loss after delivery) increased 28% in prevalence. Postpartum hemorrhage is one of today's most common complications for delivering mothers that according to the study, "markedly increases the odds of in-hospital mortality" and causes 19% of in-hospital maternal deaths.

7 May 2010

Hepcidin is found in various biological fluids, says new research

Recent studies have highlighted the importance of hepcidin in iron metabolism, particularly anaemia of chronic disease and iron overload. There have also been reports of its expression in various proinflammatory disorders and various organs, linking it to innate immunity and iron metabolism.

7 May 2010

Affymax reduces net loss to $7.9 million for first-quarter 2010

Affymax, Inc. today reported financial results for the first quarter ended March 31, 2010. The net loss for the first quarter of 2010 was $7.9 million compared to a net loss of $21.7 million for the first quarter of 2009.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Clinical development of RG7128 is on track: Pharmasset

Pharmasset, Inc., in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.

4 May 2010

Rice students' Sally Centrifuge could help diagnose anemia globally

A simple salad spinner will save lives this summer, if everything goes as planned by two Rice University undergraduates.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

Ago2 protein helps generate microRNAs: CSHL researchers

MicroRNAs are small bits of RNA within cells that wield enormous power. They influence virtually every biological process by controlling the "expression" of genes. Helping them in exerting this control is a unique class of proteins called Argonautes.

29 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Study: Lower blood oxygen levels can lead to heart abnormalities in children with sickle cell disease

Children with sickle cell disease who also have lower blood oxygen levels while both asleep and awake are likely to have heart abnormalities, researchers at Washington University School of Medicine in St. Louis and other institutions have found.

28 Apr 2010

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives - experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

28 Apr 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.

27 Apr 2010

Anemia News and Research

Further Reading

Postpartum hemorrhage increases 28% between 1995 and 2004

Hepcidin is found in various biological fluids, says new research

Affymax reduces net loss to $7.9 million for first-quarter 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Rockwell Medical first-quarter sales up 17.1%

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Clinical development of RG7128 is on track: Pharmasset

Rice students' Sally Centrifuge could help diagnose anemia globally

Novel combined immunotherapy promising for treatment of malignant brain tumors

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

FDA issues advisory on prostate cancer drugs

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Ago2 protein helps generate microRNAs: CSHL researchers

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Study: Lower blood oxygen levels can lead to heart abnormalities in children with sickle cell disease

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News